Latest news with #SimtraBioPharmaSolutions
Yahoo
18-07-2025
- Business
- Yahoo
ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing while BioNTech adds CMOs ahead of FDA filing
Pharmaceutical companies and manufacturers, including MilliporeSigma (Burlington, US), Simtra BioPharma Solutions (Parsippany, US), Carbogen AMCIS (Bubendorf, Switzerland), and BioNTech (Mainz, Germany), have recently invested to meet growing demand for antibody drug conjugates (ADCs) as targeted cancer treatments. The global ADC market was $10bn in 2023 and is anticipated to exceed $58bn by 2030 (Figure 1). According to leading data and analytics company GlobalData, ADCs are expected to lead as the largest growing group of medicines in the innovation pipeline for 2025, as the industry has seen an increase in deals to develop and manufacture ADCs. Last week, MilliporeSigma and Simtra BioPharma Solutions announced a five-year partnership to offer ADC manufacturing services to pharmaceutical companies. MilliporeSigma will offer bioconjugation manufacturing at its ADC production facility in St. Louis, Missouri, US, while Simtra will offer drug product formulation and fill-finish services. Both companies will cover the analytical work for ADC production. MilliporeSigma has a history of prioritising ADC production - the company invested $76m into its St. Louis facility in 2024, in addition to the $65m spent five years ago to build its ADC active pharmaceutical ingredient (API) site in Madison, Wisconsin, US. Last year, Simtra announced a $14m investment to expand its ADC conjugation and purification capabilities. Earlier this month, Carbogen AMCIS, an API manufacturer, along with an unnamed Japanese partner, shared that they would invest $31m to prepare two facilities in Switzerland for the commercial production of linkers by the first quarter (Q1) and Q3 2027. Another Swiss contract development and manufacturing organisation (CDMO), Lonza (Basel, Switzerland), also revealed plans to increase its ADC production capabilities last year, with the addition of two manufacturing suites to its Visp, Switzerland, site. Last month, BioNTech announced that it was preparing to file for US Food and Drug Administration (FDA) approval in second-line endometrial cancer later this year for its next-gen human epidermal growth factor receptor 2-targeted ADC, BNT323. Currently, the company is 'reliant on a China-based CDMO' to supply BNT323. However, the company shared plans to diversify its supply chain and decrease dependence on its Chinese partner by adding multiple BNT323 'supply nodes'. With impending tariffs on pharmaceuticals under the current government, there has been a rise in deals and investment to grow US manufacturing operations. Combined with the surge of ADC demand for oncology indications, clinical and commercial manufacturing contracts for ADCs are anticipated to increase. Although only 6% of the current ADC landscape is made up of marketed drugs, the ADC addressable market is expected to grow over the next decade, with 268 drugs currently in clinical stages of development (Figure 2). "ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing while BioNTech adds CMOs ahead of FDA filing" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Malaysian Reserve
01-05-2025
- Business
- Malaysian Reserve
Simtra BioPharma Solutions Releases First Sustainability Report, Underscoring Commitment to Responsible Growth
PARSIPPANY, N.J., May 1, 2025 /PRNewswire/ — Simtra BioPharma Solutions, a leading contract development and manufacturing organization (CDMO) specializing in sterile injectables, today announced the publication of its inaugural Sustainability Report for the year ended December 31, 2024. 'Since becoming an independent company in 2023, environmental, social and governance-related matters have played a vital role in shaping the way we do business, supporting our employees, our customers, and engaging with our local communities,' said Franco Negron, CEO of Simtra BioPharma Solutions. 'As such, we are proud to publish our first full-length Sustainability Report.' Key highlights of the 2024 report include: Conducted its first greenhouse gas (GHG) emissions inventory and set waste reduction goals aligned with ISO 14001 and ISO 50001 certifications, utilizing modern equipment to ensure sustainable and efficient operations. Recycled 51% of its waste across manufacturing sites and offset approximately 1,400 tons of CO2 from solar panels installed at the Germany site. Grew employee base by 26% and revamped onboarding and training programs. Completed more than 430 supplier diligence checks; became EcoVadis rated. Established a dedicated Sustainability Committee to oversee progress and drive initiatives across the organization. 'This report is a starting point,' said James Garrett, General Counsel and Chief Compliance Officer of Simtra BioPharma Solutions. 'It shows where we are today, where we need to go, and how we will hold ourselves accountable as we build the premier CDMO for injectable products.' To learn more about Simtra BioPharma Solutions' commitment to sustainability, view the full report here: Simtra Sustainability Report 2024 About Simtra BioPharma Solutions As the premier, independently owned Contract Development Manufacturing Organization with more than 65 years of sterile injectable manufacturing expertise, Simtra BioPharma Solutions offers world-class cGMP sterile fill and finish, technical expertise, quality service, and a uniquely collaborative approach to support our customers' strategic objectives. For more information, visit
